Source-grounded facts extracted from QuidelOrtho Corp's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
QuidelOrtho Corp shareholders approved Advisory vote to approve named executive officer compensation at the 2023-05-16 meeting.
“The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers by the votes set forth in the table below: Votes For Votes Against Abstentions Broker Non-Votes 50,220,763 9,027,108 75,428 3,301,745”
QuidelOrtho Corp shareholders approved Election of twelve directors to the Board at the 2023-05-16 meeting.
“The Company's stockholders elected twelve individuals to the Company's Board of Directors (the "Board") as set forth below: Name Votes For Votes Withheld Broker Non-Votes Douglas C. Bryant 58,924,173 399,126 3,301,745 Kenneth F. Buechler, Ph.D. 55,726,811 3,596,488 3,301,745 Evelyn S. Dilsaver 59,032,524 290,775 3,301,745 Edward L. Michael 58,496,050 827,249 3,301,745 Mary Lake Polan, M.D., Ph.D., M.P.H. 57,681,077 1,642,222 3,301,745 Ann D. Rhoads 58,096,675 1,226,624 3,301,745 Robert R. Schmidt 58,381,087 942,212 3,301,745 Christopher M. Smith 57,753,704 1,569,595 3,301,745 Matthew W. Strobeck, Ph.D. 59,037,340 285,959 3,301,745 Kenneth J. Widder, M.D. 52,015,394 7,307,905 3,301,745 Joseph D. Wilkins Jr. 56,753,894 2,569,405 3,301,745 Stephen H. Wise 56,879,786 2,443,513 3,301,745”
QuidelOrtho Corp reported first quarter ended April 2, 2023 results: revenue $846.1 million, EPS $0.73.
“any general incorporation language in such filing. --- EX-99.1 (EX-99.1) --- QuidelOrtho Reports First Quarter 2023 Financial Results Highligh ts • First quarter revenue of $846.1 million decreased by 16% as reported with non-respiratory revenue up 5% on a supplemental combined basis (up 7% in constant currency) and respiratory revenue down 72% on a supplemental”
QuidelOrtho Corp reported first quarter ended April 2, 2023 results: revenue $840 million to $850 million.
“today announced preliminary revenue results for the first quarter ended April 2, 2023. The Company expects total revenues in the first quarter of 2023 to be in the range of $840 million to $850 million. Respiratory product revenue is expected to be in the range of $262 million to $267 million, including COVID-19 product revenue of $212 million to $217 million.”
QuidelOrtho Corp reported full year ended January 1, 2023 results: revenue $3.27 billion, EPS $9.56.
“Full year revenue of $3.27 billion increased by 92% as reported”
QuidelOrtho Corp reported fourth quarter ended January 1, 2023 results: revenue $866.5 million, EPS $0.45.
“language in such filing. --- EX-99.1 (EX-99.1) --- QuidelOrtho Reports Fourth Quarter and Full Year 2022 Financial Results Highlights • Fourth quarter revenue of $866.5 million increased by 36% as reported and 19% on a supplemental combined basis, excluding COVID-19 revenue • Full year revenue of $3.27 billion increased by 92% as reported; Supplemental”
QuidelOrtho Corp reported the full year ended January 1, 2023 results: revenue $4,038 million to $4,053 million.
“The Company expects total revenues in the full year of 2022 to be in the range of $4,038 million to $4,053 million.”
QuidelOrtho Corp reported the fourth quarter ended January 1, 2023 results: revenue $853 million to $868 million.
“The Company expects total revenues in the fourth quarter of 2022 to be in the range of $853 million to $868 million.”
QuidelOrtho Corp: Board adopted an amendment and restatement of the Company’s Amended and Restated Bylaws, updating procedural and disclosure requirements for director nominations and business proposals, proxy card color requirements, and other updates (effective 2022-12-08).
“On December 8, 2022, as part of its periodic review of corporate governance matters and in connection with the new U.S. Securities and Exchange Commission rules regarding universal proxy cards and certain recent amendments to the Delaware General Corporation Law (the “DGCL”), the Board adopted an amendment and restatement of the Company’s Amended and Restated Bylaws (as so amended and restated, the “Amended and Restated Bylaws”), effective as of such date, in order to, among other things:”
Michael S. Iskra was appointed as Executive Vice President at QuidelOrtho Corp.
“Additionally, Mr. Bujarski, Chief Operating Officer, and Michael S. Iskra, Chief Commercial Officer, have both been appointed Executive Vice Presidents, in addition to continuing to serve in their existing leadership roles.”
Robert J. Bujarski was appointed as Executive Vice President at QuidelOrtho Corp.
“Additionally, Mr. Bujarski, Chief Operating Officer, and Michael S. Iskra, Chief Commercial Officer, have both been appointed Executive Vice Presidents, in addition to continuing to serve in their existing leadership roles.”
Douglas C. Bryant was appointed as President at QuidelOrtho Corp.
“The Board also appointed Mr. Bryant to serve, and succeed Robert J. Bujarski, as President of the Company, in addition to Mr. Bryant’s current role as Chief Executive Officer and a member of the Board.”
Kenneth F. Buechler was appointed as Chairman of the Board at QuidelOrtho Corp.
“the Company’s Board of Directors (the “Board”) appointed Kenneth F. Buechler, Lead Independent Director, to serve, and succeed Douglas C. Bryant, as the Chairman of the Board (the “Chairman”).”
QuidelOrtho Corp reported third quarter ended October 2, 2022 results: revenue $783.8 million, EPS $0.28. Guidance raised.
“The Company reported total revenue for the third quarter of 2022 of $783.8 million, a 54% increase as reported, compared to $509.8 million for the third quarter of 2021. This was largely due to the consummation of the business combination that occurred on May 27, 2022 pursuant to a Business Combination Agreement entered into as of December 22, 2021, by and among Quidel Corporation (“Quidel”), Ortho Clinical Diagnostics Holdings plc (“Ortho”), QuidelOrtho, and the other parties thereto (the “Combinations”). GAAP diluted earnings per share (EPS) for the third quarter of 2022 decreased to $0.28, compared to $5.08 for the third quarter of 2021.”
Werner Kroll was appointed as Senior Vice President, Research and Development at QuidelOrtho Corp.
“Werner Kroll, Ph.D. Senior Vice President, Research and Development”
Michelle A. Hodges was appointed as Senior Vice President, General Counsel at QuidelOrtho Corp.
“Michelle A. Hodges Senior Vice President, General Counsel”
Michael S. Iskra was appointed as Chief Commercial Officer at QuidelOrtho Corp.
“Michael S. Iskra Chief Commercial Officer”
Joseph M. Busky was appointed as Chief Financial Officer at QuidelOrtho Corp.
“Joseph M. Busky Chief Financial Officer”
Robert J. Bujarski was appointed as President and Chief Operating Officer at QuidelOrtho Corp.
“Robert J. Bujarski President and Chief Operating Officer”
Douglas C. Bryant was appointed as Chairman and Chief Executive Officer at QuidelOrtho Corp.
“Douglas C. Bryant Chairman and Chief Executive Officer”
Joseph M. Busky resigned as Sole Director at QuidelOrtho Corp.
“Immediately following the appointment of the aforementioned members of the Company’s board of directors, Joseph M. Busky resigned as the sole director of the Company.”
Evelyn Dilsaver was appointed as Member of the Board of Directors at QuidelOrtho Corp.
“On the Closing Date, the following individuals were appointed as members of the Company’s board of directors: Douglas C. Bryant, Kenneth F. Buechler, Edward L. Michael, Mary Lake Polan, Ann D. Rhoads, Matthew W. Strobeck, Kenneth J. Widder, Joseph D. Wilkins Jr., Christopher M. Smith, Stephen H. Wise, Robert R. Schmidt and Evelyn Dilsaver, each of whom, other than Mr. Bryant and Mr. Smith, qualifies as an “independent director” under the applicable rules of Nasdaq.”
Robert R. Schmidt was appointed as Member of the Board of Directors at QuidelOrtho Corp.
“On the Closing Date, the following individuals were appointed as members of the Company’s board of directors: Douglas C. Bryant, Kenneth F. Buechler, Edward L. Michael, Mary Lake Polan, Ann D. Rhoads, Matthew W. Strobeck, Kenneth J. Widder, Joseph D. Wilkins Jr., Christopher M. Smith, Stephen H. Wise, Robert R. Schmidt and Evelyn Dilsaver, each of whom, other than Mr. Bryant and Mr. Smith, qualifies as an “independent director” under the applicable rules of Nasdaq.”
Stephen H. Wise was appointed as Member of the Board of Directors at QuidelOrtho Corp.
“On the Closing Date, the following individuals were appointed as members of the Company’s board of directors: Douglas C. Bryant, Kenneth F. Buechler, Edward L. Michael, Mary Lake Polan, Ann D. Rhoads, Matthew W. Strobeck, Kenneth J. Widder, Joseph D. Wilkins Jr., Christopher M. Smith, Stephen H. Wise, Robert R. Schmidt and Evelyn Dilsaver, each of whom, other than Mr. Bryant and Mr. Smith, qualifies as an “independent director” under the applicable rules of Nasdaq.”
Christopher M. Smith was appointed as Member of the Board of Directors at QuidelOrtho Corp.
“On the Closing Date, the following individuals were appointed as members of the Company’s board of directors: Douglas C. Bryant, Kenneth F. Buechler, Edward L. Michael, Mary Lake Polan, Ann D. Rhoads, Matthew W. Strobeck, Kenneth J. Widder, Joseph D. Wilkins Jr., Christopher M. Smith, Stephen H. Wise, Robert R. Schmidt and Evelyn Dilsaver, each of whom, other than Mr. Bryant and Mr. Smith, qualifies as an “independent director” under the applicable rules of Nasdaq.”
Joseph D. Wilkins Jr. was appointed as Member of the Board of Directors at QuidelOrtho Corp.
“On the Closing Date, the following individuals were appointed as members of the Company’s board of directors: Douglas C. Bryant, Kenneth F. Buechler, Edward L. Michael, Mary Lake Polan, Ann D. Rhoads, Matthew W. Strobeck, Kenneth J. Widder, Joseph D. Wilkins Jr., Christopher M. Smith, Stephen H. Wise, Robert R. Schmidt and Evelyn Dilsaver, each of whom, other than Mr. Bryant and Mr. Smith, qualifies as an “independent director” under the applicable rules of Nasdaq.”
Kenneth J. Widder was appointed as Member of the Board of Directors at QuidelOrtho Corp.
“On the Closing Date, the following individuals were appointed as members of the Company’s board of directors: Douglas C. Bryant, Kenneth F. Buechler, Edward L. Michael, Mary Lake Polan, Ann D. Rhoads, Matthew W. Strobeck, Kenneth J. Widder, Joseph D. Wilkins Jr., Christopher M. Smith, Stephen H. Wise, Robert R. Schmidt and Evelyn Dilsaver, each of whom, other than Mr. Bryant and Mr. Smith, qualifies as an “independent director” under the applicable rules of Nasdaq.”
Matthew W. Strobeck was appointed as Member of the Board of Directors at QuidelOrtho Corp.
“On the Closing Date, the following individuals were appointed as members of the Company’s board of directors: Douglas C. Bryant, Kenneth F. Buechler, Edward L. Michael, Mary Lake Polan, Ann D. Rhoads, Matthew W. Strobeck, Kenneth J. Widder, Joseph D. Wilkins Jr., Christopher M. Smith, Stephen H. Wise, Robert R. Schmidt and Evelyn Dilsaver, each of whom, other than Mr. Bryant and Mr. Smith, qualifies as an “independent director” under the applicable rules of Nasdaq.”
Ann D. Rhoads was appointed as Member of the Board of Directors at QuidelOrtho Corp.
“On the Closing Date, the following individuals were appointed as members of the Company’s board of directors: Douglas C. Bryant, Kenneth F. Buechler, Edward L. Michael, Mary Lake Polan, Ann D. Rhoads, Matthew W. Strobeck, Kenneth J. Widder, Joseph D. Wilkins Jr., Christopher M. Smith, Stephen H. Wise, Robert R. Schmidt and Evelyn Dilsaver, each of whom, other than Mr. Bryant and Mr. Smith, qualifies as an “independent director” under the applicable rules of Nasdaq.”
Mary Lake Polan was appointed as Member of the Board of Directors at QuidelOrtho Corp.
“On the Closing Date, the following individuals were appointed as members of the Company’s board of directors: Douglas C. Bryant, Kenneth F. Buechler, Edward L. Michael, Mary Lake Polan, Ann D. Rhoads, Matthew W. Strobeck, Kenneth J. Widder, Joseph D. Wilkins Jr., Christopher M. Smith, Stephen H. Wise, Robert R. Schmidt and Evelyn Dilsaver, each of whom, other than Mr. Bryant and Mr. Smith, qualifies as an “independent director” under the applicable rules of Nasdaq.”
Edward L. Michael was appointed as Member of the Board of Directors at QuidelOrtho Corp.
“On the Closing Date, the following individuals were appointed as members of the Company’s board of directors: Douglas C. Bryant, Kenneth F. Buechler, Edward L. Michael, Mary Lake Polan, Ann D. Rhoads, Matthew W. Strobeck, Kenneth J. Widder, Joseph D. Wilkins Jr., Christopher M. Smith, Stephen H. Wise, Robert R. Schmidt and Evelyn Dilsaver, each of whom, other than Mr. Bryant and Mr. Smith, qualifies as an “independent director” under the applicable rules of Nasdaq.”
Kenneth F. Buechler was appointed as Member of the Board of Directors at QuidelOrtho Corp.
“On the Closing Date, the following individuals were appointed as members of the Company’s board of directors: Douglas C. Bryant, Kenneth F. Buechler, Edward L. Michael, Mary Lake Polan, Ann D. Rhoads, Matthew W. Strobeck, Kenneth J. Widder, Joseph D. Wilkins Jr., Christopher M. Smith, Stephen H. Wise, Robert R. Schmidt and Evelyn Dilsaver, each of whom, other than Mr. Bryant and Mr. Smith, qualifies as an “independent director” under the applicable rules of Nasdaq.”
Douglas C. Bryant was appointed as Member of the Board of Directors at QuidelOrtho Corp.
“On the Closing Date, the following individuals were appointed as members of the Company’s board of directors: Douglas C. Bryant, Kenneth F. Buechler, Edward L. Michael, Mary Lake Polan, Ann D. Rhoads, Matthew W. Strobeck, Kenneth J. Widder, Joseph D. Wilkins Jr., Christopher M. Smith, Stephen H. Wise, Robert R. Schmidt and Evelyn Dilsaver, each of whom, other than Mr. Bryant and Mr. Smith, qualifies as an “independent director” under the applicable rules of Nasdaq.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.